The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
Open accessAbstract
Purpose: Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as a key component of breast and gynecologic cancer risk-reduction for women with BRCA1 and BRCA2 mutations. Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers. Patients and Methods: A total of 1,079 women 30 years of age and older with ovaries in situ and a deleterious BRCA1 or BRCA2 mutation were enrolled onto prospective follow-up studies at one of 11 centers from November 1, 1994 to December 1, 2004. Women self-selected RRSO or observation. Follow-up information through November 30, 2005, was collected by questionnaire and medical record review. The effect of RRSO on time to diagnosis of breast or BRCA-associated gynecologic cancer was analyzed using a Cox proportional-hazards model. Results: During 3-year follow-up, RRSO was associated with an 85% reduction in BRCA1-associated gynecologic cancer risk (hazard ratio [HR] = 0.15; 95% CI, 0.04 to 0.56) and a 72% reduction in BRCA2-associated breast cancer risk (HR = 0.28; 95% CI, 0.08 to 0.92). While protection against BRCA1-associated breast cancer (HR = 0.61; 95% CI, 0.30 to 1.22) and BRCA2-associated gynecologic cancer (HR = 0.00; 95% CI, not estimable) was suggested, neither effect reached statistical significance. Conclusion: The protection conferred by RRSO against breast and gynecologic cancers may differ between carriers of BRCA1 and BRCA2 mutations. Further studies evaluating the efficacy of risk-reduction strategies in BRCA mutation carriers should stratify by the specific gene mutated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citationGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationThe Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Self-citationRisk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Self-citationRisch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Self-citationContralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationWooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 604
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Self-citationClinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer
Boyd, J. (2000) · JAMA · doi:10.1001/jama.283.17.2260 · Cited by 536
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Self-citationEisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 443
Self-citationImproved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., Eijk, R. V., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Rebbeck, T. R., Friebel, T., Wagner, T., Lynch, H. T., Garber, J. E., Daly, M. B., Isaacs, C., Olopade, O. I., Neuhausen, S. L., van ′t Veer, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.8151 · Cited by 411
Self-citationGoldgar, D. E., Easton, D. F., Deffenbaugh, A. M., Monteiro, A. N. A., Tavtigian, S. V., & Couch, F. J. (2004) · The American Journal of Human Genetics · doi:10.1086/424388 · Cited by 391
Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450401 · Cited by 385
Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., Garber, J. E., Daly, M. B., Eeles, R., Matloff, E., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327
Self-citationEstrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1061 · Cited by 293
Self-citationThe accuracy of patient reports of a family history of cancer
Love, R. R., Evans, A. M., & Josten, D. M. (1985) · Journal of Chronic Diseases · doi:10.1016/0021-9681(85)90074-8 · Cited by 251
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1260 · Cited by 239
Self-citationContribution of BRCA1 Mutations to Ovarian Cancer
Stratton, J. F., Gayther, S. A., Russell, P., Dearden, J., Gore, M., Blake, P., Easton, D., & Ponder, B. A. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361602 · Cited by 237
Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G., Burstein, H. J., Eisen, A., Lipkus, I., & Pfister, D. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.029 · Cited by 197
Rubin, S. C., Blackwood, M. A., Bandera, C., Behbakht, K., Benjamin, I., Rebbeck, T. R., & Boyd, J. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70476-4 · Cited by 179
Self-citationFrequency of germline and somatic BRCA1 mutations in ovarian cancer.
Berchuck, A., Heron, K., Carney, M. E., Lancaster, J., Fraser, E. G., Vinson, V. L., Deffenbaugh, A. M., Miron, A., Marks, J. R., Futreal, P. A., et al. (1998) · PubMed · Cited by 169
Aromatase Inhibitors for Breast Cancer Prevention
Cuzick, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.027 · Cited by 161
How Accurate is Self-Reported Family History of Colorectal Cancer?
Aitken, J., Bain, C., Ward, M., Siskind, V., & MacLennan, R. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117522 · Cited by 158
Unger, M. A., Nathanson, K. L., Calzone, K., Antin-Ozerkis, D. E., Shih, H. A., Martin, A., Lenoir, G., Mazoyer, S., & Weber, B. L. (2000) · The American Journal of Human Genetics · doi:10.1086/303076 · Cited by 157
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Boyd, J. A., Kauff, N. D., Robson, M. E., Scheuer, L., Narod, S. A., & Offit, K. (2002) · PubMed · Cited by 152
Self-citationRisk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
Kauff, N. D., & Barakat, R. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3449 · Cited by 136
Self-citationKramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9199 · Cited by 135
Bewtra, C., Watson, P. A., Conway, T., Hippee, C. R., & Lynch, H. T. (1992) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199207000-00003 · Cited by 120
Self-citationPrevalence of founderBRCA1 andBRCA2 mutations among breast and ovarian cancer patients in hungary
van der Looij, M., Szabo, C., Besznyák, I., Liszka, G., Csókay, B., Pulay, T., Tóth, J., Devilee, P., King, M., & Oláh, E. (2000) · International Journal of Cancer · Cited by 104
Rutter, J. L., Wacholder, S., Chetrit, A., Lubin, F., Menczer, J., Ebbers, S. M., Tucker, M. A., Struewing, J. P., & Hartge, P. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.14.1072 · Cited by 104
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations
Malander, S., Ridderheim, M., Måsbäck, A., Loman, N., Kristoffersson, U., Olsson, H. L., Nilbert, M. C., & Borg, Å. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.09.016 · Cited by 92
Hereditary ovarian cancer in Poland
Menkiszak, J., Gronwald, J., Górski, B., Jakubowska, A., Huzarski, T., Byrski, T., Foszczyńska‐Kłoda, M., Haus, O., Janiszewska, H., Ratajska, M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11338 · Cited by 88
Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection
Whittemore, A. S. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1334 · Cited by 81
Matsushima, M., Kobayashi, K., Eml, M., et al. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.10.1953 · Cited by 81
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer
Anton‐Culver, H., Cohen, P., Gildea, M., & Ziogas, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00110-6 · Cited by 80
Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation
Klaren, H. M., Veer, L. J. V., van Leeuwen, F. E., & Rookus, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.941 · Cited by 78
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium.
Narod, S. A., Ford, D., Devilee, P., Barkardottir, R. B., Eyfjord, J. E., Lenoir, G., Serova, O., Easton, D. F., & Goldgar, D. E. (1995) · Europe PMC (PubMed Central) · Cited by 75
Petrucelli, N., Lazebnik, N., Huelsman, K. M., & Lazebnik, R. S. (2002) · Genetic Testing · doi:10.1089/10906570260199357 · Cited by 74
(2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.05.002 · Cited by 67
Piek, J. M. J., Torrenga, B., Hermsen, B. B. J., Verheijen, R. H. M., Zweemer, R. P., Gille, J. J. P., Kenemans, P., van Diest, P. J., & Menko, F. H. (2003) · Familial Cancer · doi:10.1023/a:1025700807451 · Cited by 66
Rafnar, Þ., Benediktsdóttir, K. R., Eldon, B., Gestsson, T., Saemundsson, H., Olafsson, K., Salvarsdottir, A., Steingrı́msson, E., & Thorlacius, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.09.008 · Cited by 62
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study
Bjørge, T., Lie, A. K., Hovig, E. J., Gislefoss, R. E., Hansen, S., Jellum, E., Langseth, H., Nustad, K., Tropé, C. G., & Dørum, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602199 · Cited by 57
Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions
Hartmann, L. C., Degnim, A. C., & Schaid, D. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.925 · Cited by 55
Rates of Jewish Ancestral Mutations in BRCAI and BRCA2 in Borderline Ovarian Tumors
Gotlieb, W. H., Ben‐Baruch, G., Friedman, E., Bar-Sade, R. B., Сергеевна, К. А., Hirsh‐Yechezkel, G., Modan, B., Novikov, I., Davidson, B., Kopolovic, J., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.995 · Cited by 50
Cited by
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Self-citationkConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationCancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Self-citationRebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citation
Metadata
- Authors
- Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., Neuhausen, S. L., Daly, M. B., Matloff, E., Blum, J. L., Sabbatini, P., Barakat, R. R., Hudis, C., Norton, L., Offit, K., & Rebbeck, T. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-10
- Volume
- 26
- Issue
- 8
- Pages
- 1331-1337
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152217620
- Cited by
- 589
- References
- 60
- FWCI
- 24.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.